我們已在上線！進一步了解

Longboard Pharmaceuticals, Inc. Common Stock

LBPH

市值 US$23.4億

已下市

LBPH已於2024年11月29日下市。

返回排名列表

關於： Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

員工： 33

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 0%

負面 0%

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp OCEAN Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in participants two years of age and older. “The initiation of our secon.

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported third quarter 2024 financial results. RECENT UPDATES: In October, announced an agreement for H. Lundbeck A/S (Lundbeck) to acquire Longboard in a strategic deal Bexicaserin (LP352), an oral, centrally acting, 5-HT2C superagonist in development f.

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Longboard Pharmaceuticals, Inc. (NasdaqGM: LBPH) to H. Lundbeck A/S. Under the terms of the proposed transaction, shareholders of Longboard will receive $60.00 in cash for each share of Longboard that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. – LBPH

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Longboard Pharmaceuticals, Inc . (Nasdaq : LBPH ), relating to a tender offer from H. Lundbeck A/S. Under the terms of the agreement, H. Lundbeck offers to acquire outstanding shares of Longboard common stock for $60.00 per share.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. – LBPH

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Longboard Pharmaceuticals, Inc. (NasdaqGM: LBPH) to H. Lundbeck A/S. Under the terms of the proposed transaction, shareholders of Longboard will receive $60.00 in cash for each share of Longboard that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and OB on Behalf of Shareholders

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and OB on Behalf of Shareholders

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. - LBPH

NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH ), relating to a tender offer from H.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. - LBPH

Zacks Investment Research

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%

LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.

NEW YORK , Oct. 14, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) and its board of directors concerning the proposed acquisition of the company by H. Lundbeck A/S.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.

查看新聞排名

價格圖表採用Lightweight Charts™實作